Severe alopecia areata (AA) was long treated off-label with systemic immunosuppressants or unapproved topical agents. Between 2022 and 2024, the FDA approved three oral Janus kinase (JAK) inhibitors specifically for severe alopecia areata: Eli Lilly’s Olumiant (baricitinib, June 2022), Pfizer’s Litfulo (ritlecitinib, June 2023), and Sun Pharma’s Leqselvi (deuruxolitinib, July 2024).
These approvals created a competitive specialty dermatology category. However, with annual wholesale acquisition costs (WAC) surpassing $50,000 to $57,000, commercial payers and pharmacy benefit managers (PBMs) have erected stringent prior authorization (PA) criteria, re-examination rules, and step-therapy hurdles. The landscape also saw a much-anticipated generic entrant: generic tofacitinib (Xeljanz) launched in June 2026. But unlike most generic launches, early generic tofacitinib pricing has stayed high (~$57/tablet, ~$41,000/year at 5mg BID) rather than collapsing to a low off-label floor — so for now it is a modestly cheaper alternative, not yet a category-disrupting price benchmark.
This analysis evaluates the coverage criteria, acquisition costs, patent exclusivity timelines, adolescent age indications, and billing realities across all three FDA-approved agents and the newly launched generic tofacitinib.
Direct Answer & Key Takeaways
Direct Answer: Three oral JAK inhibitors are FDA-approved for severe alopecia areata: Olumiant (baricitinib, approved June 2022, adult dose 2mg/4mg daily), Litfulo (ritlecitinib, approved June 23, 2023, approved down to age 12, dose 50mg daily, WAC $4,384.13/28-day supply
$57K/year), and Leqselvi (deuruxolitinib, approved July 25, 2024, adult dose 8mg BID). All carry the unified FDA class boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events (MACE), and thrombosis. Litfulo and Leqselvi are dispensed exclusively through specialty pharmacy channels, while Olumiant maintains retail National Average Drug Acquisition Cost (NADAC) benchmarks ($92.29/2mg tablet). Branded patent protection extends to 2028–2044. Generic tofacitinib (Xeljanz) launched in June 2026 after pediatric exclusivity expired, but early generic pricing ($57/tablet, ~$41K/year at 5mg BID) remains far above the deep-discount levels seen for most generics — it is not FDA-approved for alopecia areata, so any use is off-label.
+-------------------------------------------------------------------------------------------------------+
| ALOPECIA AREATA JAK INHIBITOR MATRIX |
+------------------+-----------------------+-----------------------+------------------------------------+
| Drug (Sponsor) | Approval / Indication | Age Floor & Dosing | WAC / NADAC Benchmark (2026 Data) |
+------------------+-----------------------+-----------------------+------------------------------------+
| Olumiant | June 2022 | Adults (>=18 yrs) | NADAC: $92.29 / 2mg tablet |
| (baricitinib) | Oral JAK1/JAK2 | 2mg QD (4mg severe) | ~$2,768.70 / 30-day supply |
+------------------+-----------------------+-----------------------+------------------------------------+
| Litfulo | June 2023 | Adolescents & Adults | WAC: $4,384.13 / 28-cap bottle |
| (ritlecitinib) | Oral JAK3/TEC dual | (>=12 yrs), 50mg QD | ~$57,150 / annual WAC |
+------------------+-----------------------+-----------------------+------------------------------------+
| Leqselvi | July 2024 | Adults (>=18 yrs) | Commercial Specialty Channels |
| (deuruxolitinib) | Oral JAK1/JAK2 | 8mg BID (twice daily) | Retail Est.: ~$4,587.51 / 30-day |
+------------------+-----------------------+-----------------------+------------------------------------+
| Generic Xeljanz | IR Tablets Launched | Off-Label Reference | Brand NADAC: $73.83 / 5mg tablet |
| (tofacitinib) | June 2026 | (Not FDA-Approved AA) | Generic ~$57/tab (~$41K/yr at 5mg |
| | | | BID) — discount not yet materialized|
+------------------+-----------------------+-----------------------+------------------------------------+
Which Alopecia Areata JAK Inhibitors Do Payers Cover and What Is the Step Therapy?
Payer coverage across commercial plans, Medicare Advantage, and state Medicaid programs exhibits significant variation, but shares common prior authorization structure. Because alopecia areata was historically classified by some health plans as a cosmetic condition rather than an autoimmune disease, formulary policies explicitly require objective documentation of clinical severity before approving coverage.
Prior Authorization Criteria Standard
To secure initial prior authorization for Olumiant, Litfulo, or Leqselvi, specialty pharmacy submission packages must typically document:
- Severity Baseline: A baseline Severity of Alopecia Tool (SALT) score of (\ge 50%) scalp hair loss (defining severe alopecia areata). Some plans enforce a stricter threshold of (\ge 75%) loss.
- Exclusion of Secondary Causes: Documented exclusion of androgenetic alopecia, trichotillomania, telogen effluvium, or scar-inducing dermatologic conditions.
- Contraceptive and Screening Protocols: Baseline negative tuberculosis (TB) screening, Hepatitis B/C serology, complete blood count (CBC) absolute neutrophil count (ANC (\ge 1,000/\mu\text{L})), lymphocyte count ((\ge 500/\mu\text{L})), and baseline lipid panel, given class-wide laboratory monitoring requirements.
- Step-Therapy Requirements: Most plans mandate a trial and failure (or documented medical contraindication) of super-potent topical corticosteroids (e.g., clobetasol propionate 0.05% under occlusion for 12 weeks) or intralesional triamcinolone acetonide injections.
+---------------------------------------+
| Initial Diagnosis: Severe Alopecia |
| Areata (SALT Score >= 50%) |
+---------------------------------------+
|
v
+---------------------------------------+
| Step 1: High-Potency Topical Steroids |
| or Intralesional Triamcinolone |
+---------------------------------------+
|
[Inadequate Response / Failed]
|
v
+---------------------------------------+
| Step 2: Baseline Screenings |
| (TB, Hep B/C, CBC, LFTs, Lipids) |
+---------------------------------------+
|
v
+-------------------------------------+-------------------------------------+
| | |
v v v
+-----------------------+ +-----------------------+ +-----------------------+
| Age 12 - 17 Years | | Adult (Preferred) | | Adult (Non-Preferred) |
| First-Line Biologic | | Formulary Agent | | Exception Pathway |
+-----------------------+ +-----------------------+ +-----------------------+
| | |
v v v
+-----------------------+ +-----------------------+ +-----------------------+
| Litfulo (ritlecitinib)| | Olumiant or Litfulo | | Leqselvi or Branded |
| 50mg QD Approved | | Initial 6-Month Trial | | Second-Line Agent |
+-----------------------+ +-----------------------+ +-----------------------+
Re-Authorization and Renewal Hurdles
Formulary approvals are typically granted for an initial 6-month trial window. Re-authorization at 6 to 12 months requires documented evidence of clinical response, typically defined as achieving a SALT score (\le 20) (representing 80% or greater scalp hair coverage) or a relative improvement of (\ge 50%) from baseline (SALT-50). If hair regrowth is insufficient at the 24-week mark, plans enforce mandatory discontinuation or switching rather than dose escalation, except for Olumiant where step-up from 2mg to 4mg daily is allowed under specific FDA label parameters for refractory severe disease.
For broader context on systemic therapy access structures across related autoimmune dermatoses, see our comprehensive review of the atopic dermatitis systemic access landscape.
What Do Litfulo, Leqselvi, and Olumiant Cost at WAC and NADAC?
The commercial pricing structure of the alopecia areata JAK inhibitor cohort reflects distinct specialty versus retail distribution strategies.
WAC and Retail Acquisition Costs
- Litfulo (ritlecitinib): Pfizer’s Connecticut Prescriber Price Disclosure documents a Wholesale Acquisition Cost (WAC) of $4,384.13 per 28-capsule 50mg bottle, which translates to an annual WAC expenditure of approximately $57,149.55 for a 365-day regimen (assuming continuous daily dosing of one capsule per day).
- Olumiant (baricitinib): Eli Lilly’s Olumiant is available through retail pharmacy chains and national wholesalers. Based on Centers for Medicare & Medicaid Services (CMS) National Average Drug Acquisition Cost (NADAC) benchmarks:
- Olumiant 2mg tablet: $92.29 per unit (~$2,768.70 per 30-day supply; ~$33,685 per year).
- Olumiant 4mg tablet: $184.66 per unit (~$5,539.80 per 30-day supply; ~$67,398 per year).
- Leqselvi (deuruxolitinib): Sun Pharma commercialized Leqselvi following a patent dispute settlement with Incyte. Distributed exclusively through contracted specialty pharmacies, retail price aggregators list 60-tablet 8mg supplies (a 30-day supply at 8mg twice daily) at approximately $4,587.51, yielding an annualized retail baseline near $55,050.
+--------------------------------------------------------------------------------------------------------+
| ANNUAL ACQUISITION COST COMPARISON (2026) |
+-------------------------------+-----------------------+---------------------+--------------------------+
| Product / Dose | Channel | Unit Price | Annualized Benchmark |
+-------------------------------+-----------------------+---------------------+--------------------------+
| Olumiant 2mg QD | Retail (NADAC) | $92.29 / tab | $33,685 |
| Olumiant 4mg QD | Retail (NADAC) | $184.66 / tab | $67,398 |
| Litfulo 50mg QD | Specialty (WAC) | $156.58 / cap equivalent | $57,150 |
| Leqselvi 8mg BID | Specialty (Est.) | $76.46 / tab equivalent | $55,050 |
| Xeljanz 5mg BID (Brand Reference) | Retail (NADAC) | $73.83 / tab | $53,896 |
| Generic Tofacitinib 5mg BID | Retail (Generic) | ~$57 / tab (post-launch)| ~$41,400 (Aug 2026) |
+-------------------------------+-----------------------+---------------------+--------------------------+
The Generic Tofacitinib Launch — High So Far, Not a Cheap Floor
The generic pricing baseline is anchored by Pfizer's brand Xeljanz (tofacitinib 5mg), which shows a retail NADAC of $73.83 per tablet ($53,896/year for 5mg twice daily). Generic tofacitinib citrate immediate-release tablets (5mg, 10mg) received FDA approval and launched commercially in June 2026 (Aurobindo, Breckenridge, Apotex, Sun, Zydus, and others), following the June 8, 2026 expiration of pediatric exclusivity that had extended NDA 208246 protections past the December 2025 patent expiry. The extended-release 11mg generic (Ajanta) had been approved separately in August 2025.
So far, however, the generic has not delivered the 80–90% discount typical of small-molecule generics. Roughly two months after launch (August 2026), generic tofacitinib 5mg still sells near $57 per tablet (~$41,400/year at 5mg BID) — only about 20–25% below brand. This is the documented "specialty-generic" pattern (seen previously with imatinib/Gleevec), in which limited early competition, PBM rebate dynamics, and a small generic field keep launch-period pricing elevated; deeper discounts typically arrive only as more entrants and authorized generics accumulate. Payers should treat the ~$41K/year figure as the current reality, not the eventual generic floor.
Although tofacitinib is not FDA-approved for alopecia areata (its labeled indications cover rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and polyarticular juvenile idiopathic arthritis), off-label clinical literature documents its efficacy in hair regrowth. Notably, reviewed payer step-therapy policies for the on-label alopecia JAK inhibitors generally require prior trial/failure of conventional systemic agents (corticosteroids, methotrexate, cyclosporine) and topical/intralesional therapies — and typically prohibit combining any JAK inhibitors, including tofacitinib — rather than mandating off-label tofacitinib first.
For an overarching analysis of PBM pricing mechanisms and drug acquisition data, review our guide to NADAC price lookup functionality and limits.
When Do Alopecia JAK Patents Expire and When Does Generic Tofacitinib Launch?
Formulary decision-makers tracking multi-year specialty budgets rely on Loss of Exclusivity (LOE) timelines and FDA Orange Book patent listings to forecast when generic competition will reduce category spend.
+--------------------------------------------------------------------------------------------------------+
| ORANGE BOOK EXCLUSIVITY & PATENT WALLS |
+-------------------+-------------+-------------------+--------------------+-----------------------------+
| Product (Appl No) | Sponsor | Active Ingredient | NCE Exclusivity | Latest Listed Patent Expiry |
+-------------------+-------------+-------------------+--------------------+-----------------------------+
| Olumiant (207924) | Eli Lilly | Baricitinib | Expired | May 31, 2032 (US 8,158,616) |
| Litfulo (215830) | Pfizer | Ritlecitinib | June 23, 2028 | Oct 17, 2041 (US 12,116,368)|
| Leqselvi (217900) | Sun Pharma | Deuruxolitinib | July 25, 2029 | Oct 10, 2044 (US 12,364,699)|
| Xeljanz (203214) | Pfizer | Tofacitinib | Expired | Generic Launch Mid-2026 |
+-------------------+-------------+-------------------+--------------------+-----------------------------+
Orange Book Patent Analysis
- Litfulo (ritlecitinib, Application 215830):
- New Chemical Entity (NCE) Exclusivity: Expires June 23, 2028.
- Patent Wall: Listed Orange Book patents extend protection out to October 17, 2041 (U.S. Patent 12,116,368, covering specific crystalline forms, formulation matrix compositions, and targeted kinase binding methods).
- Leqselvi (deuruxolitinib, Application 217900):
- NCE Exclusivity: Expires July 25, 2029.
- Deuterated Technology Patent Wall: Sun Pharma’s acquisition of Concert Pharmaceuticals secured deuterated chemical compound patents. Orange Book listings extend to October 10, 2044 (U.S. Patent 12,364,699).
- Olumiant (baricitinib, Application 207924):
- Exclusivity Expiration: Primary NCE exclusivity has lapsed.
- Patent Wall: Primary substance patents (U.S. Patent 8,420,629) expire March 10, 2029, with secondary formulation patents extending to May 31, 2032 (U.S. Patent 8,158,616).
- Generic Tofacitinib Launch Window:
- Generic tofacitinib immediate-release tablets launched commercially in June 2026 (Aurobindo, Breckenridge, Apotex, Sun, Zydus), once the June 8, 2026 pediatric-exclusivity extension on NDA 208246 expired. The extended-release 11mg generic was approved separately in August 2025. Early post-launch pricing remains elevated (~$57/tablet), well above a deep-discount generic floor.
For detailed methodology on analyzing Orange Book patent cliffs and generic entry timelines, consult our report on the generic launch opportunity scorecard.
How Does Litfulo Differ for Adolescents Versus Adult-Only Leqselvi and Olumiant?
Age indication boundaries create operational partition lines in specialty pharmacy prior authorization workflows.
+------------------------------------------------------------------------------------------------------+
| AGE INDICATION & DOSING DIVERGENCE |
+-------------------+-------------------+--------------------+-----------------------------------------+
| Drug | Approved Age | Regimen | Pediatric/Adolescent Coverage Impact |
+-------------------+-------------------+--------------------+-----------------------------------------+
| Litfulo | >= 12 Years | 50mg Once Daily | Sole FDA-approved oral JAK for |
| (ritlecitinib) | (Adolescents & | (Capsule) | patients aged 12 to 17 years. |
| | Adults) | | Exempt from adult-only step therapy. |
+-------------------+-------------------+--------------------+-----------------------------------------+
| Olumiant | >= 18 Years | 2mg Once Daily | Off-label in pediatric AA. Prior |
| (baricitinib) | (Adults Only) | (4mg if severe) | authorization requires age exception. |
+-------------------+-------------------+--------------------+-----------------------------------------+
| Leqselvi | >= 18 Years | 8mg Twice Daily | Adult-only label. Higher daily pill |
| (deuruxolitinib) | (Adults Only) | (BID Tablet) | burden (2 tabs/day vs 1 tab/day). |
+-------------------+-------------------+--------------------+-----------------------------------------+
Pediatric and Adolescent Market Exclusivity
Litfulo holds a unique position as the only systemic alopecia areata treatment FDA-approved for adolescents aged 12 to 17 years. In pivotal clinical trials (ALLEGRO Phase 2b/3), ritlecitinib demonstrated statistically significant scalp hair regrowth (SALT (\le 20)) in both adolescent and adult cohorts with 50mg daily dosing.
This age floor grants Pfizer a protected monopoly in pediatric and adolescent alopecia areata access:
- Formulary Step-Bypassing: When a patient aged 12–17 presents with severe alopecia areata, PBM policies cannot force a step-through Olumiant, Leqselvi, or off-label generic tofacitinib, as those agents lack FDA approval for pediatric alopecia areata.
- Specialty Hub Navigation: Pfizer’s specialty support hub (Litfulo Coverage Plus) leverages this adolescent label status to challenge commercial insurance denials, securing rapid tier exceptions for pediatric patients.
Conversely, both Olumiant and Leqselvi are restricted to adults (\ge 18) years of age. Attempts to prescribe Olumiant or Leqselvi to pediatric patients face automated PBM claim rejections based on age-edit rules, requiring formal medical director appeals and clinical justification.
Kinase Selectivity, Black Box Warnings, and Laboratory Monitoring
Understanding the underlying pharmacodynamic differences helps clarify safety profiles and clinical trial designs across the class.
+------------------------------------------------------------------------------------------------------+
| KINASE SELECTIVITY & MONITORING COMPARISON |
+-------------------+-------------------------+----------------------+---------------------------------+
| Target Drug | Primary Kinase Targets | Dosing Schedule | Laboratory Baseline Requirements|
+-------------------+-------------------------+----------------------+---------------------------------+
| Litfulo | Irreversible JAK3 / | 50mg QD | CBC (Platelets, ALC, ANC), |
| (ritlecitinib) | TEC Kinase Family | | Hep B/C, TB, Lipids |
+-------------------+-------------------------+----------------------+---------------------------------+
| Olumiant | Reversible JAK1 / | 2mg or 4mg QD | CBC (Platelets, ALC, ANC), |
| (baricitinib) | JAK2 Inhibitor | | Renal Function (eGFR), LFTs |
+-------------------+-------------------------+----------------------+---------------------------------+
| Leqselvi | Reversible JAK1 / | 8mg BID | CBC, LFTs, TB, Hep B/C, |
| (deuruxolitinib) | JAK2 Inhibitor | | Baseline Lipid Panel |
+-------------------+-------------------------+----------------------+---------------------------------+
Mechanistic Differences
- Litfulo (ritlecitinib): An irreversible, highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases. By blocking JAK3 and TEC family members, it inhibits interleukin-2 (IL-2), IL-4, IL-7, IL-9, IL-15, and IL-21 signaling without significantly inhibiting JAK1 or JAK2, potentially sparing JAK2-dependent erythropoietin and thrombopoietin pathways.
- Olumiant (baricitinib) & Leqselvi (deuruxolitinib): Reversible selective JAK1 and JAK2 inhibitors. By interrupting signaling downstream of interferon-gamma (IFN-(\gamma)) and IL-6, they suppress the auto-reactive CD8+ T-cell attack on hair follicle immune privilege. Leqselvi incorporates deuterium substitution at key metabolic sites, altering hepatic CYP-mediated clearance and allowing targeted 8mg BID dosing.
FDA Class Boxed Warning Alignment
Despite biochemical differences in kinase selectivity, the FDA enforces a unified Class Boxed Warning across Litfulo, Leqselvi, and Olumiant. Derived from long-term safety signals observed in the ORAL Surveillance trial of pan-JAK inhibitor tofacitinib in rheumatoid arthritis, all alopecia JAK labels warn of:
- Serious Infections: Increased risk of active tuberculosis, invasive fungal infections, and opportunistic viral infections (including herpes zoster reactivation).
- Mortality: Higher rate of all-cause mortality reported with JAK inhibitors compared to TNF blockers.
- Malignancy: Increased incidence of lymphomas, non-melanoma skin cancers (NMSC), and lung cancers.
- Major Adverse Cardiovascular Events (MACE): Elevated risk of cardiovascular death, myocardial infarction, and stroke.
- Thrombosis: Increased rates of pulmonary embolism (PE), deep vein thrombosis (DVT), and arterial thrombosis.
For a broader evaluation of safety signal tracking and regulatory oversight, examine our reference analysis on JAK inhibitor class access dynamics and FDA boxed warning vs EMA regulatory restrictions.
What Is the J-Code and Medical-vs-Pharmacy Benefit Billing Reality?
A frequent source of claim rejections and dispensing delays is benefit channel confusion.
Pharmacy Benefit vs Medical Benefit Routes
Because Olumiant, Litfulo, and Leqselvi are oral self-administered solid dosage forms (tablets and capsules), they are processed almost exclusively through the Pharmacy Benefit using National Drug Codes (NDCs) rather than through the Medical Benefit.
+------------------------------------------------------------------------------------------------------+
| BENEFIT CHANNEL & BILLING SUMMARY |
+-------------------+--------------------+------------------------+------------------------------------+
| Drug | Billing Channel | HCPCS / J-Code Status | Primary Processing Identifier |
+-------------------+--------------------+------------------------+------------------------------------+
| Litfulo 50mg | Pharmacy Benefit | No specific J-Code | 11-digit NDC (e.g., 00069-1000-28) |
| (ritlecitinib) | (Specialty Hub) | (Self-Administered) | NCPDP Electronic Claim Processing |
+-------------------+--------------------+------------------------+------------------------------------+
| Olumiant 2mg/4mg | Pharmacy Benefit | Miscellaneous J3490 | 11-digit NDC (e.g., 00002-4182-30) |
| (baricitinib) | (Retail / Mail) | (Rarely Used) | NCPDP Electronic Claim Processing |
+-------------------+--------------------+------------------------+------------------------------------+
| Leqselvi 8mg | Pharmacy Benefit | No specific J-Code | 11-digit NDC (e.g., 47335-0123-60) |
| (deuruxolitinib) | (Specialty Hub) | (Self-Administered) | NCPDP Electronic Claim Processing |
+-------------------+--------------------+------------------------+------------------------------------+
- No Dedicated Buy-and-Bill J-Codes: Unlike infused biologics (e.g., IV infliximab or rituximab), oral JAK inhibitors do not possess dedicated Healthcare Common Procedure Coding System (HCPCS) J-codes for office-administered buy-and-bill reimbursement.
- Miscellaneous Billing Errors: Practices that attempt to bill oral Litfulo or Leqselvi under unassigned medical codes (such as J3490 or J8499) encounter claim rejections from commercial medical claims payers.
- Accumulator and Maximizer Programs: Because these oral agents are billed through pharmacy benefit management systems, commercial patients are frequently exposed to copay accumulator adjustment programs (CAAPs) and copay maximizers. When manufacturer copay assistance cards are exhausted or disallowed by PBM copay accumulators, out-of-pocket patient costs can spike to full coinsurance (e.g., 20% to 33% of WAC, amounting to $1,000–$1,800/month), triggering high initial abandonment rates at specialty pharmacies.
To review billing mechanics and copay accumulator defense strategies in specialty pharmacy workflows, see our operational guide to specialty drug copay accumulator appeal workflows.
Frequently Asked Questions
Is generic tofacitinib (Xeljanz) available for alopecia areata yet and what does it cost?
Generic tofacitinib citrate immediate-release tablets launched in June 2026 (Aurobindo, Breckenridge, Apotex, Sun, Zydus), once pediatric exclusivity on Xeljanz expired. It is not FDA-approved for alopecia areata (its labeled indications are rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and polyarticular juvenile idiopathic arthritis), so any alopecia use is off-label. Roughly two months after launch (August 2026), generic tofacitinib 5mg still costs about $57 per tablet (~$41,400/year at 5mg twice daily) — only modestly below brand Xeljanz, because early specialty-generic pricing has stayed high. Deeper discounts may arrive as more generic entrants and authorized generics accumulate.
Which alopecia areata drug is approved for adolescents under 18?
Pfizer’s Litfulo (ritlecitinib) is the only systemic alopecia areata medication FDA-approved for adolescents aged 12 to 17 years (at a recommended dose of 50mg once daily). Both Olumiant (baricitinib) and Leqselvi (deuruxolitinib) are FDA-approved exclusively for adult patients aged 18 and older.
Do Litfulo, Leqselvi, and Olumiant share the same boxed warning?
Yes. Although Litfulo is a dual JAK3/TEC inhibitor while Olumiant and Leqselvi target JAK1/JAK2, the FDA mandates a unified Class Boxed Warning across all oral JAK inhibitors. This warning highlights serious risks of severe infections, all-cause mortality, malignancies (including lymphoma and skin cancers), major adverse cardiovascular events (MACE), and thrombosis (DVT/PE).
Sources
- U.S. Food and Drug Administration (FDA): FDA Approves First Treatment for Severe Alopecia Areata (Olumiant/baricitinib Approval Notice, June 2022). https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-severe-alopecia-areata
- Pfizer Inc.: FDA Approves Pfizer's LITFULO (ritlecitinib) for Adults and Adolescents 12 Years and Older with Severe Alopecia Areata (Press Release, June 2023). https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-pfizers-litfulotm-ritlecitinib-adults-and
- Pfizer Connecticut Prescriber Price Disclosure: Litfulo (ritlecitinib) Wholesale Acquisition Cost (WAC) Disclosure (January 2026). https://cdn.pfizer.com/pfizercom/products/ctprescribers/LITFULOCTPriceDisclosureShortForm01092026.pdf
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Litfulo Appl 215830; Leqselvi Appl 217900; Olumiant Appl 207924). https://www.accessdata.fda.gov/scripts/cder/ob/
- Centers for Medicare & Medicaid Services (CMS): National Average Drug Acquisition Cost (NADAC) Monthly Files (2026 Snapshot). https://www.medicaid.gov/medicaid/prescription-drugs/registration-and-use-national-average-drug-acquisition-cost-nadac/index.html
- DailyMed / U.S. National Library of Medicine: LITFULO (ritlecitinib) Prescribing Information & Boxed Warning. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1882f799-9065-4f36-97bc-b34e2c040683
- Drugs.com: Generic Xeljanz (tofacitinib) Availability, Approval History, and Pricing (June 2026 IR-tablet launches; August 2025 XR approval; post-launch cash price). https://www.drugs.com/availability/generic-xeljanz.html
